Concepedia

Manoli Vourvahis

MV

30

Publications

1.1K

Citations

21

H-Index

2008

Active since

Affiliations

Pfizer (United States)(Current)

Pfizer (United Kingdom)

ViiV Healthcare (United Kingdom)

Pfizer (Belgium)

University of Liverpool

Manoli Vourvahis is an author at Pfizer (United States) specializing in pharmacology, medicine, and pharmacotherapy.

Top concepts

PharmacologyMedicinePharmacotherapyHivPharmacokineticsHealthPathologyHepatologyImmunologyEngineering

Publications per year

2008–2023

30

Publications

30

Maraviroc: Pharmacokinetics and drug Interactions

David Back, Manoli Vourvahis · Antiviral Therapy · 2009 · 117 citations · Full text

Drug Interactions, Maraviroc Exposure, Pharmacological Study +12

Dose‐Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs

Daiki Mori, Emi Kimoto, Brian Rago et al. · Clinical Pharmacology & Therapeutics · 2019 · 101 citations · Full text

The Pharmacokinetics of Silymarin Is Altered in Patients with Hepatitis C Virus and Nonalcoholic Fatty Liver Disease and Correlates with Plasma Caspase-3/7 Activity

Sarah J. Schrieber, Zhiming Wen, Manoli Vourvahis et al. · Drug Metabolism and Disposition · 2008 · 80 citations

A Phenotype–Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir

Julie B. Dumond, Manoli Vourvahis, Nardin Rezk et al. · Clinical Pharmacology & Therapeutics · 2010 · 62 citations

Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment

John D. Davis, Caroline E. Ridgway, Julia Hamlin et al. · Antiviral Therapy · 2008 · 59 citations

Rows per page

1–5 of 30